Education
About Us
Working with TipRanks
Follow Us
Pacific Biosciences (PACB)
NASDAQ:PACB
PACB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.07 - $2.72
Previous CloseN/A
Volume8.28M
Average Volume (3M)8.26M
Market Cap
$339.05M
Enterprise Value$845.63M
Total Cash (Recent Filing)$147.65M
Total Debt (Recent Filing)$3.04M
Price to Earnings (P/E)―
Beta1.25
Next Earnings
May 08, 2025EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.62
Shares Outstanding300,041,320
10 Day Avg. Volume6,570,572
30 Day Avg. Volume8,263,226
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap2.49
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit22.68
Enterprise Value/Ebitda-2.21
Forecast
1Y Price Target
$2.10Price Target Upside85.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
---
Bulls Say, Bears Say
Bulls Say
Market ExpansionManagement feels better about their serviceable addressable market due to ongoing technology and cost improvements, and expansion into clinical markets.
Product LaunchThe launch of Vega should unlock a new portion of the market for PacBio, and recent advancements to Revio should help the product rebound.
Production And CostsPacBio expects to achieve full-scale production for Vega manufacturing in 2H25, which should help boost gross margins.
Bears Say
Macroeconomic ConditionsChallenging macro conditions, limited visibility into recovery timing, and demand elasticity likely keep the stock range bound.
Revenue GuidanceThe '25 sales guidance is 13% below consensus, reflecting pressure from NIH funding and broader macroeconomic factors.
Sales CycleRevio pushouts and macro headwinds weigh on the quarter, resulting in a lower guidance to reflect capex pressure and a longer sales cycle following the Vega launch.
---
Ownership Overview
2.96% Insiders
10.94% Mutual Funds
0.65% Other Institutional Investors
63.10% Public Companies and
Individual Investors
PACB FAQ
What was Pacific Biosciences’s price range in the past 12 months?
Pacific Biosciences lowest stock price was $1.07 and its highest was $2.72 in the past 12 months.
What is Pacific Biosciences’s market cap?
Pacific Biosciences’s market cap is $339.05M.
When is Pacific Biosciences’s upcoming earnings report date?
Pacific Biosciences’s upcoming earnings report date is May 08, 2025 which is in 9 days.
How were Pacific Biosciences’s earnings last quarter?
Pacific Biosciences released its earnings results on Feb 13, 2025. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of -$0.19 by $0.2.
Is Pacific Biosciences overvalued?
According to Wall Street analysts Pacific Biosciences’s price is currently Undervalued.
Does Pacific Biosciences pay dividends?
Pacific Biosciences does not currently pay dividends.
What is Pacific Biosciences’s EPS estimate?
Pacific Biosciences’s EPS estimate is -0.19.
How many shares outstanding does Pacific Biosciences have?
Pacific Biosciences has 300,041,320 shares outstanding.
What happened to Pacific Biosciences’s price movement after its last earnings report?
Pacific Biosciences reported an EPS of $0.01 in its last earnings report, beating expectations of -$0.19. Following the earnings report the stock price went up 25%.
Which hedge fund is a major shareholder of Pacific Biosciences?
Currently, no hedge funds are holding shares in PACB
---
Pacific Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.10 (85.84% Upside)
$2.10 (85.84% Upside)
Blogger Sentiment
Bearish
PACB Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $741.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.12%
12-Months-Change
Fundamentals
Return on Equity
-51.11%
Trailing 12-Months
Asset Growth
-27.81%
Trailing 12-Months
Company Description
Pacific Biosciences
Pacific Biosciences (PACB), headquartered in Menlo Park, California, is a prominent biotechnology company specializing in the development of advanced sequencing technologies. The company is best known for its innovative Single Molecule, Real-Time (SMRT) sequencing platforms, which provide high-resolution insights into genetic sequences. These platforms are utilized in various sectors, including life sciences research, agriculture, and clinical diagnostics, to enable comprehensive genomic analysis and discovery.
---
PACB Company Deck
---
PACB Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
PacBio demonstrated strong growth in genomic data output and consumable revenue, along with successful product launches and cost reductions. However, significant challenges remain, including a substantial decline in instrument revenue, macroeconomic and funding uncertainties, and extended cash flow breakeven timeline due to recent challenges.Read More>---
PACB Stock 12 Month Forecast
Average Price Target
$2.10
▲(85.84% Upside)
Technical Analysis
---